Intranasal vaccine developer AuraVax Therapeutics said that the company has licensed liposomal STING agonist technology from Massachusetts General Hospital (MGH) for use as an adjuvant in vaccines against COVID-19 and other respiratory diseases. The technology was developed by MGH researcher Mei X. Wu. AuraVax co-founder Navin Varadarajan commented, "We are … [Read more...] about AuraVax Therapeutics licences intranasal vaccine adjuvant technology from Massachusetts General Hospital
Business
Acorda sells Inbrija manufacturing operations to Catalent
Catalent will pay Acorda Therapeutics $80 million cash for Acorda's manufacturing operations in Chelsea, MA, USA where the company makes Inbrija dry powder levodopa. According to Catalent, the 90,000 sq ft CGMP facility "will act as a global center of excellence within the Catalent network for spray-dried dispersion and dry powder encapsulation and … [Read more...] about Acorda sells Inbrija manufacturing operations to Catalent
Arcturus Therapeutics to develop inhaled CFTR mRNA therapy for CF
California-based Arcturus Therapeutics announced that it will develop its ARCT-032 aerosolized CFTR mRNA formulation for the treatment of cystic fibrosis. According to Arcturus, preclinical studies of ARCT-032, which is based on the company's LUNAR (lipid-enabled and unlocked nucleomonomer agent modified RNA) technology, have demonstrated that the inhaled therapy has … [Read more...] about Arcturus Therapeutics to develop inhaled CFTR mRNA therapy for CF
United Therapeutics to acquire priority review voucher for use with Tyvaso DPI NDA
United Therapeutics announced that it has agreed to pay $105 million for a rare pediatric disease priority review voucher that the company plans to use to get an 8-month FDA review of an NDA for its Tyvaso treprostinil DPI instead of the standard 12-month review. Submission of the NDA for the treatment of pulmonary arterial hypertension and pulmonary hypertension … [Read more...] about United Therapeutics to acquire priority review voucher for use with Tyvaso DPI NDA
Menarini acquires rights to market Ryaltris nasal spray in 33 European countries
Menarini will pay Glenmark an undisclosed amount up front plus milestone payments for exclusive rights to market Ryaltris olopatadine/mometasone furoate nasal spray in 33 European countries, Ryaltris developer Glenmark has announced. Glenmark will be continue to be responsible for European development and regulatory approval of the nasal spray for the treatment of … [Read more...] about Menarini acquires rights to market Ryaltris nasal spray in 33 European countries
Tonix to develop intranasal oxytocin for the treatment of insulin resistance and obesity
Several months after acquiring the rights to TNX-1900 oxytocin nasal spray for the treatment of migraine headaches from Trigemina, Tonix Pharmaceuticals announced that it has acquired an exclusive license to technology from the University of Geneva for the use of oxytocin to treat insulin resistance and related conditions such as obesity. The company has not yet … [Read more...] about Tonix to develop intranasal oxytocin for the treatment of insulin resistance and obesity
Hikma gets FDA approval for, and launches, generic version of Advair Diskus
Hikma Pharmaceuticals announced that the FDA has approved 100 mcg/50 mcg and 250 mcg/50 mcg doses of the company's fluticasone propionate / salmeterol DPI (VR315), a generic version of Advair Diskus and that the company has launched the inhaler in the US. The FDA had issued a minor CRL in response to the ANDA in September 2020. A previous CRL had been issued in May … [Read more...] about Hikma gets FDA approval for, and launches, generic version of Advair Diskus
Opiant gets additional $3.5 million from BARDA for development of intranasal nalmefene
According to Opiant Pharmaceuticals, the US Biomedical Advanced Research and Development Authority (BARDA) is providing an additional $3.5 million for development of Opiant's OPNT003 nalmefene nasal spray for the treatment of opioid overdose. BARDA had previously provided $4.6 million. The company has also received funding from the National Institute on Drug … [Read more...] about Opiant gets additional $3.5 million from BARDA for development of intranasal nalmefene
UofL researchers get $8.5 million from US Department of Defense for Q-Griffithsin nasal spray development
The US Department of Defense is providing $8.5 million to fund development of a Q-Griffithsin (Q-GRFT) nasal spray at the University of Louisville, the university said. The funding will support the PREVENT-CoV project for development of a once-daily nasal spray for the prevention of viral infections through a Phase 1 study. Researchers say that because they already … [Read more...] about UofL researchers get $8.5 million from US Department of Defense for Q-Griffithsin nasal spray development
Cyrano raises almost $13 million for Phase 2 trial of intranasal theophylline to restore sense of smell
Cyrano Therapeutics announced that it has raised $12.8 million in Series A financing to allow it to complete a Phase 2 trial of its CYR-064 intranasal theophylline for the restoration of the senses of smell and taste. In October 2017, Cyrano announced that it had partnered with Shanghai Newsummit Biopharma for development of the nasal spray in China; the new funding … [Read more...] about Cyrano raises almost $13 million for Phase 2 trial of intranasal theophylline to restore sense of smell